

( (S (NP-SBJ (NP G.D. Searle & Co.)
             ,
             (NP a Monsanto Co. unit)
             ,)
     (VP is
         (VP launching
             (NP (NP a program)
		 (SBAR (WHNP-2 0)
		       (S (NP-SBJ *T*-2)
			  (VP to
			      (VP give
				  (NP consumers)
				  (NP (NP more information)
				      (PP about
					  (NP its drugs)))
				  (SBAR-TMP (WHADVP-1 when)
					    (S (NP-SBJ doctors)
					       (VP prescribe
						   (NP them)
						   (ADVP-TMP *T*-1)))))))))))
     .))
( (S (S-ADV (NP-SBJ-1 *-3)
	    (VP Called
		(S (NP-SBJ *-1)
		   (NP-PRD (NP Patients)
			   (PP in
			       (NP the Know))))))
     ,
     (NP-SBJ-3 the program)
     (VP features
	 (NP (NP-SBJ-2 fact sheets)
	     (VP designed
		 (S (NP-SBJ *-2)
		    (VP to
			(VP be
			    (ADJP-PRD easy
				      (SBAR (WHNP-4 0)
					    (S (NP-SBJ *)
					       (VP to
						   (VP understand
						       (NP *T*-4))))))))))))
     .))
( (S (NP-SBJ The sheets)
     (VP (VP tell
             (SBAR (WHADVP-1 how)
                   (S (NP-SBJ the medicine)
                      (VP works
			  (ADVP-MNR *T*-1)))))
         ,
         (VP describe
             (SBAR (WHADVP-2 how)
                   (S (NP-SBJ *)
                      (VP to
                          (VP use
                              (NP it)
			      (ADVP-MNR *T*-2))))))
         and
         (VP list
             (NP its possible side effects)))
     .))
( (S (NP-SBJ-3 They)
     (VP (VP are
	     (VP designed
		 (S (NP-SBJ-1 *-3)
		    (VP to
			(VP be
			    (VP given
				(NP *-1)
				(PP-CLR to
					(NP patients))
				(PP by
				    (NP-LGS their doctors))
				(SBAR-TMP (WHADVP-4 when)
					  (S (NP-SBJ-2 the medicines)
					     (VP are
						 (VP prescribed
						     (NP *-2)
						     (ADVP-TMP *T*-4)))))))))))
	 and
	 (VP include
	     (NP (NP space)
		 (SBAR (WHADVP-6 0)
		       for
		       (S (NP-SBJ-5 the doctor)
			  (VP to
			      (S (NP-SBJ *-5)
				 (VP write
				     (NP special instructions)
				     (ADVP-LOC *T*-6)))))))))
     .))
( (S (PP In
         (NP addition))
     ,
     (NP-SBJ Searle)
     (VP will
         (VP give
             (NP pharmacists)
             (NP (NP brochures)
                 (PP on
                     (NP (NP the use)
                         (PP of
                             (NP prescription drugs))))
                 (PP for
		     (NP (NP distribution)
			 (PP-LOC in
				 (NP their stores)))))))
     .))
( (S (NP-SBJ Consumer groups)
     (VP have
         (ADVP-TMP long)
         (VP advocated
             (SBAR that
                   (S (NP-SBJ (NP drug companies)
                              and
                              (NP doctors))
                      (VP make
                          (S (NP-SBJ more information)
			     (ADJP-PRD available
				       (PP to
					   (NP patients)))))))))
     .))
( (SINV ``
	(S-TPC-2 (NP-SBJ We)
		 (VP believe
		     (SBAR that
			   (S (NP-SBJ (NP every drug)
				      (SBAR (WHNP-1 that)
					    (S (NP-SBJ-3 *T*-1)
					       (VP 's
						   (VP marketed
						       (NP *-3)
						       (PP-CLR to
							       (NP a consumer)))))))
			      (VP should
				  (VP have
				      (NP a consumer label)))))))
	, 
	''
	(VP said
	    (S *T*-2))
	(NP-SBJ (NP Douglas Teich)
		(PP of
		    (NP (NP the Public Citizen Health Research Group)
			,
			(NP a Ralph Nader affiliate))))
	.))
( (S (NP-SBJ Dr. Teich)
     (VP said
         (SBAR 0
               (S (NP-SBJ Searle)
                  (VP is
		      ``
                      (NP-PRD (NP the only company)
                              (SBAR (WHNP-2 0)
                                    (S (NP-SBJ I)
                                       (VP know
                                           (NP *T*-2))))
                              (SBAR (WHNP-1 that)
                                    (S (NP-SBJ *T*-1)
				       (VP (ADVP-MNR voluntarily)
					   ''
					   will
                                           (VP make
                                               (S (NP-SBJ consumer information)
						  (ADJP-PRD available)))))))))))
     .))
( (S (PP According
         (PP to
	     (NP (NP federal officials) and (NP drug-industry studies))))
     ,
     (NP-SBJ (NP nearly half)
	     (PP of
		 (NP (NP the (ADJP 1.6 billion) prescriptions)
		     (VP filled
			 (NP *)
			 (NP-TMP each year)))))
     (VP are n't
	 (VP used
	     (ADVP-MNR properly)
	     ,
	     (S-ADV (NP-SBJ *)
		    (VP meaning
			(SBAR that
			      (S (S (NP-SBJ-1 money)
				    (VP is
					(VP wasted
					    (NP *-1)
					    (PP-CLR on
						    (NP some prescriptions)))))
				 and
				 (S (NP-SBJ-2 patients)
				    (VP are
					(VP deprived
					    (NP *-2)
					    (PP-CLR of
						    (NP (NP the benefits)
							(PP of
							    (NP medication)))))))))))))
     .))
( (SINV ``
	(S-TPC-3 (NP-SBJ We)
		 (VP think
		     (SBAR 0
			   (S (NP-SBJ (NP it)
				      (S *EXP*-1))
			      (VP 's
				  (ADJP-PRD very important)
				  (S-1 (NP-SBJ *)
				       (VP to
					   (VP provide
					       (NP (NP as much information)
						   (PP as
						       (ADJP possible))
						   (PP on
						       (NP (NP the drugs)
							   (SBAR (WHNP-2 0)
								 (S (NP-SBJ consumers)
								    (VP take
									(NP *T*-2)))))))))))))))
	, 
	''
	(VP said
	    (S *T*-3))
	(NP-SBJ Searle Chairman
		Sheldon Gilgore)
	.))
